US Senate Measure Highlights ‘Warm-Base’ Manufacturing Capacity For Next Pandemic Response
Executive Summary
Committee's bipartisan discussion draft for legislation outlines lessons learned from COVID-19 pandemic response, including need for greater manufacturing facility readiness. Meanwhile, congressional oversight agency calls for “transformation” of response efforts.
You may also be interested in...
How Should The US Government Coordinate Emergency Clinical Trials?
Research institutions, CROs, biopharma industry and other stakeholders are asked to comment on potential governance structure that would determine when trials are needed to address disease outbreaks and other public health emergencies.
Global Supply Chain Scrutiny And Investment In Domestic Alternatives For US Drug Shortages
Pharmaceutical supply chains may grow less efficient and less risk prone as US government gets more involved to ensure availability of pandemic and essential medicines. But what about pediatric oncology medicines and other treatments that save lives even though they may not be considered essential?
Time To End The Myth-Making About COVID Vaccine Reviews
The COVID vaccine development ‘miracle’ is already a core narrative of the pandemic era. But as the US prepares to apply lessons going forward, it is important to recognize the ways the process should not be a model for ‘normal’ operations, especially at FDA.